An observational study in Peripheral Arterial Disease, Superficial Femoral Artery Stenosis and Angiopathy, Peripheral, sponsored by Cardionovum GmbH. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Cardionovum GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 29th largest by enrollment of the 47 observational ones that give a count, is one of 14 that started in 2022, is one of 47 observational ones, reaches primary completion later than 17 of the 28 other live ones, and was the 138th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18–85
Biotronik AG · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18+
CSL Behring · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
University of Leipzig · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 19 · Phase 4 5
First in 2001; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is below the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 107 across the 126 interventional studies, 200 across the 47 observational. Of the 118 that completed or were terminated, 34 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 173 have an industry lead sponsor. The 10 most frequent:
Cardionovum GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Cardionovum GmbH has 2 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971772Cardionovum GmbHSIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries | 2026-12 |
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT06832631OrbusNeichVITUS Post-Market Registry | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to demonstrate the superiority in safety and efficacy of the Legflow DCB vs standard uncoated POBA in a randomized controlled (RCT) for treatment of patients with symptomatic peripheral artery disease (PAD) due to stenosis, restenosis or occlusion of the femoral and/or popliteal arteries.
Patients with peripheral arterial disease in the SFA, eligible for treatment with the paclitaxel coated Legflow dilatation balloon catheter
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
treatment with Drug Coated Balloon angioplasty with the Legflow .035" Paclitaxel Balloon Dilatation catheter.
treatment with standard POBA (uncoated) angioplasty (type and brand at the physician's discretion)
Primary Efficacy Endpoint:
The primary efficacy endpoint is time to clinically-driven target lesion revascularization (CD-TLR) at 12 months, defined as any reintervention at the target lesion due to symptoms OR drop of ankle brachial index (ABI) \> 20 % OR ABI \> 0.15 compared to the post-procedural ABI.
Time frame: 12 months post-procedure
Device- and procedure-related death
Primary Safety Endpoint: Freedom from device- and procedure-related death through 30 days post-index procedure;
Time frame: 30 days post-procedure
Major target limb amputation and clinically-driven target vessel revascularization
Primary Safety Endpoint: A composite of (2.1) time to major target limb amputation (above-the-ankle (ATA)) through 12 months post-procedure and (2.2) time to clinically-driven target vessel revascularization (CD-TVR) through 12 months post-index procedure
Time frame: 12 months post-procedure
Acute device success
defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure
Time frame: during index procedure
Acute procedural success
Acute procedural success is defined as restoration of the target lesion with ≤30% residual stenosis in the final angiogram.
Time frame: during index procedure
Secondary safety endpoint at discharge up to 30 days post-index procedure
Secondary safety endpoint is a composite of (3.1) freedom from all cause death (3.2) freedom from major target limb amputation (3.3) freedom from CD-TVR
Time frame: 30 days post-operative
Sustained clinical improvement at 6-, 12- and 24- months post-index procedure
Clinical improvement is defined as a composite of (4.1) freedom from major target limb amputation, (4.2) freedom from TVR, (4.3) freedom from worsening target limb Rutherford class (compared to baseline) (4.4) freedom from decrease in target limb ankle brachial index (ABI) ≥0.15 (compared to baseline)
Time frame: 6, 12, 24-months post-procedure
Major Adverse Events (MAEs) at 6-, 12- and 24-months post-index procedure
MAEs are defined as composite of (5.1) all-cause death, (5.2) CD-TVR (5.3) major target limb amputation (5.4) thrombosis at the target lesion
Time frame: 6, 12, 24-months post-procedure
Primary Patency at 6-, 12- and 24-months
The primary patency is defined as a composite of (6.1) freedom from clinically-driven target lesion revascularization (CD-TLR) (6.2) freedom from binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis) • For discharge and 12-months: assessed by independent Core Lab
Time frame: 6, 12, 24-months post-procedure
Target Lesion Revascularization at 6-, 12- and 24-months post-index procedure
defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure.
Time frame: 6, 12, 24-months post-procedure
Target Vessel Revascularization at 6-, 12- and 24-months post-index procedure
defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure
Time frame: 6, 12, 24-months post-procedure
Binary restenosis at 6-, 12- and 24-months
defined as a restenosis confirmed by DUS PSVR ≥2.4 or ≥50% stenosis (For 12-month: assessed by Independent Core-Lab)
Time frame: 6, 12, 24-months post-procedure
Major Target Limb Amputation at 6-, 12- and 24-months
defined as an amputation above the ankle (ATA) in the target limb
Time frame: 30- days, 6, 12, 24-months post-procedure
Thrombosis at the target lesion at 6-, 12- and 24-months
Thrombosis at the target lesion at 6-, 12- and 24-months
Time frame: 6, 12, 24-months post-procedure
All-cause death at 6-, 12- and 24-months
All-cause death at 6-, 12- and 24-months
Time frame: 30- days, 6, 12, 24-months post-procedure
Change in target limb Rutherford Classification from baseline to 6-, 12- and 24-months
Change in Target Limb Rutherford Classification from baseline to 6-, 12- and 24-months
Time frame: 6, 12, 24-months post-procedure
Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months
Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months
Time frame: 6, 12, 24-months post-procedure
Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.
Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.
Time frame: 6, 12, 24-months post-procedure
device- and procedure-related death
Freedom from device- and procedure-related death at discharge, 30 days, 6-, 12- and 24-months
Time frame: 30- days, 6, 12, 24-months post-procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 54 months is above that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardionovum GmbH